Latest filing published 06 Feb 2026 for Taysha Gene Therapies, Inc., €6,331.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Kamran Alam in Taysha Gene Therapies, Inc., where the filings describe the role as finance chief. The record holds 22 filings, for trades running from 23 September 2020 to 4 February 2026.
The open-market record consists of 14 sales worth €1.2M, with no purchase. The rest of the record consists of 8 share grants. Since January 2026: no purchases and 3 sales on the market.
The latest filing, published on 6 February 2026, reports an open-market sale of €6,331 in Taysha Gene Therapies, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations